Fludroxycortide cream as an alternative therapy for actinic cheilitis
- 13 Downloads
The objective of the study is to assess, by clinical follow-up, the efficacy of the dermatological cream Fludroxycortide 0.125 mg/g (Drenison®) in the treatment of actinic cheilitis (AC).
Material and methods
Twenty-three patients diagnosed with AC participated in the study. Fifteen were submitted to corticotherapy with Fludroxycortide, applied three times a day for up to 6 weeks, associated with lip sunscreen (LS) before sun exposure. In the control group of eight patients, only the use of LS was established. At each weekly return, a photographic record was made of the lesion. After treatment, images were evaluated and scores were assigned to verify clinical evolution. Also, patients treated with Fludroxycortide responded to a questionnaire, to assess drug tolerability and treatment satisfaction.
In the group treated with Fludroxycortide (n = 15), five patients showed total improvement, seven presented partial improvement, and three showed no clinical change. Concerning the patients treated with LS (n = 8), one presented total remission of the clinical lesion characteristics, four exhibited partial improvement, and three exhibited no clinical lip alteration. No case presented symptom worsening. Of the 15 patients undergoing corticotherapy, 12 were satisfied and reported that the product was not irritating and contributed to lesion improvement.
Conventional treatment with LS was effective in the remission of some AC lesions, but treatment responses were improved when associated with Fludroxycortide, especially in the more severe cases.
As it is a non-invasive therapy leading, in most cases, to adequate clinical results, safety, and tolerability, Fludroxycortide can be considered an effective alternative treatment for AC.
KeywordsLip Inflammation Cheilitis Sunscreen Flurandrenolone
This study was funded by the authors and supported by the Department of Dentistry, Federal University of Rio Grande do Norte.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Ethics Committee of the Federal University of Rio Grande do Norte (Protocol 1.846.133).
Informed consent was obtained from all individual participants included in the study.
- 1.Freddo AL, Vogt BF, Torriani MA, Hosni ES (2009) Vermilionectomy: a treatment alternative for actinic cheilitis. Rev odonto ciênc 24(3):319–322Google Scholar
- 2.Bertini FR, Sgarbi FC, Tera TM, Brandão AAH, Cavalcante ASR (2010) Histological analysis of the actinic cheilitis: an interobserver approach. Int J Dent 9(1):6–10Google Scholar
- 10.Wood NH, Khammissa R, Meyerov R, Lemmer J, Feller L (2011) Actinic cheilitis: a case report and a review of the literature. Eur J Dent 5(1):101–106Google Scholar
- 18.CORDRAN® SP CREAM (2013) San Antonio: Manufactured by DPT Laboratories, 2013. Bula de remédio. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/012806s037lbl.pdf. Acessed 28 April 2018
- 19.DRENISON® (2014) Farmacêutico responsável: Dr. Dante Alario Junior São Paulo: Avert Laboratórios Ltda, 2014 Bula de remédio http://wwwanvisagovbr/datavisa/fila_bula/frmVisualizarBulaasp?pNuTransacao=9007102014&pIdAnexo=2253250. Acessed 28 April 2018
- 21.Nelson CG, Spencer J, Nelson CG Jr (2007) A single-arm, open-label efficacy and tolerability study of diclofenac sodium 3% gel for the treatment of actinic keratosis of the upper and lower lip. J Drugs Dermatol 6(7):712–717Google Scholar
- 26.Cox DP, Ferreira L (2017) The Oral effects of inhalation corticosteroid therapy: an update. J Calif Dent Assoc 45(5):227–233Google Scholar